Dataset Information

Human gut microbes impact host serum metabolome and insulin sensitivity

ABSTRACT: Insulin resistance is a forerunner state of ischaemic cardiovascular disease and type 2 diabetes. Here we show how the human gut microbiome impacts the serum metabolome and associates with insulin resistance in 277 non-diabetic Danish individuals. The serum metabolome of insulin-resistant individuals is characterized by increased levels of branched-chain amino acids (BCAAs), which correlate with a gut microbiome that has an enriched biosynthetic potential for BCAAs and is deprived of genes encoding bacterial inward transporters for these amino acids. Prevotella copri and Bacteroides vulgatus are identified as the main species driving the association between biosynthesis of BCAAs and insulin resistance, and in mice we demonstrate that P. copri can induce insulin resistance, aggravate glucose intolerance and augment circulating levels of BCAAs. Our findings suggest that microbial targets may have the potential to diminish insulin resistance and reduce the incidence of common metabolic and cardiovascular disorders.

INSTRUMENT(S): GCxGC-TOFMS (LECO Pegasus 4D), UPLC-QTOFMS (Waters QTOF Premier)

SUBMITTER: Matej Oresic

PROVIDER: MTBLS351 | MetaboLights | 2017-08-31

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	MTBLS351	Other
	a_GCxGC_mass_spectrometry.txt	Txt
	a_UPLC_mass_spectrometry.txt	Txt
	a_metahitmetabolomics_metabolite_profiling_mass_spectrometry-1.txt	Txt
	a_metahitmetabolomics_metabolite_profiling_mass_spectrometry.txt	Txt

Items per page:

1 - 5 of 13

Publications

Human gut microbes impact host serum metabolome and insulin sensitivity.

Pedersen Helle Krogh HK Gudmundsdottir Valborg V Nielsen Henrik Bjørn HB Hyotylainen Tuulia T Nielsen Trine T Jensen Benjamin A H BA Forslund Kristoffer K Hildebrand Falk F Prifti Edi E Falony Gwen G Le Chatelier Emmanuelle E Levenez Florence F Doré Joel J Mattila Ismo I Plichta Damian R DR Pöhö Päivi P Hellgren Lars I LI Arumugam Manimozhiyan M Sunagawa Shinichi S Vieira-Silva Sara S Jørgensen Torben T Holm Jacob Bak JB Trošt Kajetan K Kristiansen Karsten K Brix Susanne S Raes Jeroen J Wang Jun J Hansen Torben T Bork Peer P Brunak Søren S Oresic Matej M Ehrlich S Dusko SD Pedersen Oluf O

Nature 20160713 7612

Insulin resistance is a forerunner state of ischaemic cardiovascular disease and type 2 diabetes. Here we show how the human gut microbiome impacts the serum metabolome and associates with insulin resistance in 277 non-diabetic Danish individuals. The serum metabolome of insulin-resistant individuals is characterized by increased levels of branched-chain amino acids (BCAAs), which correlate with a gut microbiome that has an enriched biosynthetic potential for BCAAs and is deprived of genes encod ...[more]

PMID: 27409811

Publication: 1/3

Similar Datasets

Project description:Pancreatic cancer is the 3rd most prevalent cause of cancer related deaths in United states alone, with over 55000 patients being diagnosed in 2019 alone and nearly as many succumbing to it. Late detection, lack of effective therapy and poor understanding of pancreatic cancer systemically contributes to its poor survival statistics. Obesity and high caloric intake linked co-morbidities like type 2 diabetes (T2D) have been attributed as being risk factors for a number of cancers including pancreatic cancer. Studies on gut microbiome has shown that lifestyle factors as well as diet has a huge effect on the microbial flora of the gut. Further, modulation of gut microbiome has been seen to contribute to effects of intensive insulin therapy in mice on high fat diet. In another study, abnormal gut microbiota was reported to contribute to development of diabetes in Db/Db mice. Recent studies indicate that microbiome and microbial dysbiosis plays a role in not only the onset of disease but also in its outcome. In colorectal cancer, Fusobacterium has been reported to promote therapy resistance. Certain intra-tumoral bacteria have also been shown to elicit chemo-resistance by metabolizing anti-cancerous agents. In pancreatic cancer, studies on altered gut microbiome have been relatively recent. Microbial dysbiosis has been observed to be associated with pancreatic tumor progression. Modulation of microbiome has been shown to affect response to anti-PD1 therapy in this disease as well. However, most of the studies in pancreatic cancer and microbiome have remained focused om immune modulation. In the current study, we observed that in a T2D mouse model, the microbiome changed significantly as the hyperglycemia developed in these animals. Our results further showed that, tumors implanted in the T2D mice responded poorly to Gemcitabine/Paclitaxel (Gem/Pac) standard of care compared to those in the control group. A metabolomic reconstruction of the WGS of the gut microbiota further revealed that an enrichment of bacterial population involved in drug metabolism in the T2D group.